Judy Hackett received her Pharmacy Degree from the University of Toronto. She subsequently completed her M.B.A. at York University. As well she has a graduate degree in Evaluation and Outcomes from the Faculty of Medicine, University of Toronto. She began her career working in community pharmacy and then went onto work as a payer where she developed and managed drug formularies as well as evaluated DUR reports. She has worked for over 20 years in the pharmaceutical industry in the government affairs, health economics and pricing. Judy is currently Global Payer Evidence Director at AstraZeneca.
Ms. Hackett will be speaking at World Anti-Microbial Resistance Congress USA 2016 about IMI: DRIVE AB: Driving reinvestment in R&D for antibiotics and advocating their responsible use’ This session will cover how DRIVE-AB is helping reduce antimicrobial resistance through responsible antibiotic use, working towards novel business models needed to revive reinvestment in antibiotics, and helping determine future public health needs by estimating the current and future impact of antibiotic resistance on societies. To hear from Judy Hackett and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016 held September 8-9 in Washington, DC.